Advertisement

Spektrum der Augenheilkunde

, Volume 12, Issue 3, pp 114–116 | Cite as

Orale Ganciclovirtherapie bei makulärer CMV-Retinitis

  • Irene Ruhswurm
  • Eva Ries
  • G. Koitz
  • Katharina Krepler
  • Agnes Derbolav
  • A. Wedrich
Originalarbeiten
  • 25 Downloads

Oral ganciclovir as maintenance treatment of macular CMV-retinitis

Zusammenfassung

Es wird der Einsatz von oralem Ganciclovir als Erhaltungstherapie bei Cytomegalovirus (CMV)-retinitis im Bereich des hinteren Pols diskutiert. Wir berichten über einen 42 Jahre alten HIV-positiven Patienten mit einem makulären CMV-Herd. Nach der intravenösen Induktionstherapie mit Ganciclovir erhielt der Patient eine orale Erhaltungstherapie mit Ganciclovir. Nach 50 Tagen kam es trotz nur minimaler Aktivitätszeichen zu einer Progression des zentralen Herdes mit massivem Visusabfall.

Unsere ersten Erfahrungen mit dem Einsatz von oralem Ganciclovir sprechen gegen die Verwendung von oralem Ganciclovir als Erhaltungstherapie bei CMV-Herden nahe der Fovea, bzw. des Sehnerven, da bei CMV-Herden nahe der Fovea und des Optikus schon eine geringe Progression einen massiven Visusabfall bedeutet.

Summary

We herein discuss the use of oral ganciclovir for the maintenance-treatment of macular cytomegalovirus (CMV)-lesions. A 42 years old patient with acquired immunodeficiency syndrome (AIDS) with a CMV-retinitis close to the fovea is presented. After induction therapy with intravenous ganciclovir the patient was treated with oral ganciclovir maintenance therapy. After 50 days of oral ganciclovir therapy CMV-retinitis progressed without signs of active borders, causing a severe loss of visual acuity. With oral ganciclovir maintenance therapy progression of retinitis might be more difficult to detect. Therefore oral ganciclovir may not be appropriate for the treatment of lesions at the posterior pole, where minimal degree of progression may have major visual consequences.

Schlüsselwörter

Cytomegalovirus (CMV)-retinitis orales Ganciclovir Erhaltungstherapie acquired immunodeficiency syndrome (AIDS) 

Key words

Cytomegalovirus (CMV)-retinitis oral ganciclovir maintenance-treatment acquired immunodeficiency syndrome (AIDS) 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Drew LW, Ives D, Lalezari JP, et al (1995) Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 333: 615–620PubMedCrossRefGoogle Scholar
  2. 2.
    Henderly DE, Freeman WR, Causey DM, Rao NA (1987) Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94: 425–434PubMedGoogle Scholar
  3. 3.
    Jabs DA, Green WR, Fox R, et al (1989) Ocular manifestations of the acquired immunodeficiency syndrome. Ophthalmology 96: 1092–1099PubMedGoogle Scholar
  4. 4.
    Jabs DA, Newman C, De Bustros S, Polk BF (1987) Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94: 824–830PubMedGoogle Scholar
  5. 5.
    Holland GN, Sidikaro Y, Kreiger AE, et al (1987) Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94: 815–823PubMedGoogle Scholar
  6. 6.
    Holland GN, Shuler JD (1992) Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol 110: 1435–1442PubMedGoogle Scholar
  7. 7.
    Holland GN, Tufail A (1995) New therapies for cytomegalovirus retinitis. N Engl J Med 333: 658–659PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobson MA, Wulfsohn M, et al (1994) Phase II dose-ranking trial of foscarnet salvage therapy for cytomegal ovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir. AIDS 8: 451–459PubMedCrossRefGoogle Scholar
  9. 9.
    Kupperman BD, Flored-Aguilar M, Quiceno J, et al (1993) Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Arch Ophthalmol 111: 1359–1366Google Scholar
  10. 10.
    Plotkin SA, Drew WL, Felsenstein D, et al (1985) Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanin on human cytomegalovirus replication in vitro. J Infect Dis 152: 833–834PubMedGoogle Scholar
  11. 11.
    Roarty JD, Fisher EJ, Nussbaum J (1993) Long-term visual morbidity of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Ophthalmology 100: 1685–1688PubMedGoogle Scholar
  12. 12.
    Spector SA, Busch DF, Follansbee S, et al (1993) Pharmacokinetic, safety and antiviral profile of oral ganciclovir in HIV-infected persons (ACTG 127) First National Conference on Human Retroviruses and Related Infections. Washington, DC [abstract 539]Google Scholar
  13. 13.
    The Oral Ganciclovir European and Australian Cooperative Study Group (1995) Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 9: 471–477Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • Irene Ruhswurm
    • 1
  • Eva Ries
    • 1
  • G. Koitz
    • 1
  • Katharina Krepler
    • 1
  • Agnes Derbolav
    • 1
  • A. Wedrich
    • 1
  1. 1.Universitätsklinik für Augenheilkunde und OptometrieWien

Personalised recommendations